Hsbc Holdings PLC Grows Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Hsbc Holdings PLC grew its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR) by 148.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 46,222 shares of the company’s stock after purchasing an additional 27,605 shares during the period. Hsbc Holdings PLC’s holdings in Vir Biotechnology were worth $405,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of VIR. GAMMA Investing LLC increased its stake in shares of Vir Biotechnology by 249.9% during the first quarter. GAMMA Investing LLC now owns 2,708 shares of the company’s stock valued at $27,000 after buying an additional 1,934 shares during the period. Innealta Capital LLC purchased a new position in shares of Vir Biotechnology during the second quarter valued at $32,000. PNC Financial Services Group Inc. increased its stake in shares of Vir Biotechnology by 20.1% during the fourth quarter. PNC Financial Services Group Inc. now owns 11,186 shares of the company’s stock valued at $113,000 after buying an additional 1,869 shares during the period. Quest Partners LLC grew its stake in Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after purchasing an additional 7,452 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Vir Biotechnology in the first quarter valued at about $119,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total transaction of $95,082.00. Following the completion of the sale, the director now owns 11,616 shares of the company’s stock, valued at $90,604.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 15.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on VIR. Barclays lifted their target price on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Needham & Company LLC lifted their target price on Vir Biotechnology from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Finally, Morgan Stanley lifted their target price on Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Thursday, June 6th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $36.80.

Vir Biotechnology Stock Performance

Shares of VIR stock opened at $7.56 on Wednesday. Vir Biotechnology, Inc. has a fifty-two week low of $7.12 and a fifty-two week high of $13.09. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.89 and a beta of 0.46. The stock’s 50-day simple moving average is $8.44 and its 200-day simple moving average is $9.19.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The business had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $7.53 million. During the same quarter in the previous year, the firm posted ($1.45) EPS. Vir Biotechnology’s revenue was down 19.0% on a year-over-year basis. As a group, equities analysts forecast that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).